-
1
-
-
0022349817
-
Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer
-
Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 1985;313:1485-92.
-
(1985)
N Engl J Med
, vol.313
, pp. 1485-1492
-
-
Rosenberg, S.A.1
Lotze, M.T.2
Muul, L.M.3
Leitman, S.4
Chang, A.E.5
Ettinghausen, S.E.6
-
2
-
-
0023115642
-
A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone
-
Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 1987;316:889-97.
-
(1987)
N Engl J Med
, vol.316
, pp. 889-897
-
-
Rosenberg, S.A.1
Lotze, M.T.2
Muul, L.M.3
Chang, A.E.4
Avis, F.P.5
Leitman, S.6
-
3
-
-
0023123517
-
Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer
-
West WH, Tauer KW, Yannelli JR, Marshall GD, Orr DW, Thurman GB, et al. Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 1987;316:898-905.
-
(1987)
N Engl J Med
, vol.316
, pp. 898-905
-
-
West, W.H.1
Tauer, K.W.2
Yannelli, J.R.3
Marshall, G.D.4
Orr, D.W.5
Thurman, G.B.6
-
4
-
-
0023926926
-
Influence of dose and duration of infusion of interleukin-2 on toxicity and immunomodulation
-
Thompson JA, Lee DJ, Lindgren CG, Benz LA, Collins C, Levitt D, et al. Influence of dose and duration of infusion of interleukin-2 on toxicity and immunomodulation. J Clin Oncol 1988;6:669-78.
-
(1988)
J Clin Oncol
, vol.6
, pp. 669-678
-
-
Thompson, J.A.1
Lee, D.J.2
Lindgren, C.G.3
Benz, L.A.4
Collins, C.5
Levitt, D.6
-
5
-
-
0025241161
-
Interleukin-2 and lymphokine-activated killer cell therapy: Analysis of a bolus interleukin-2 and a continuous infusion interleukin 2 regimen
-
Clark JW, Smith JW, Steis RG, Urba WJ, Crum E, Miller R, et al. Interleukin-2 and lymphokine-activated killer cell therapy: analysis of a bolus interleukin-2 and a continuous infusion interleukin 2 regimen. Cancer Res 1990;50:7343-50.
-
(1990)
Cancer Res
, vol.50
, pp. 7343-7350
-
-
Clark, J.W.1
Smith, J.W.2
Steis, R.G.3
Urba, W.J.4
Crum, E.5
Miller, R.6
-
6
-
-
0023890374
-
Clinical and immunological effects of recombinant interleukin-2 given by repetitive weekly cycles to patients with cancer
-
Sondel PM, Kohler PC, Hank JA, Moore KH, Rosenthal NS, Sosman JA, et al. Clinical and immunological effects of recombinant interleukin-2 given by repetitive weekly cycles to patients with cancer. Cancer Res 1988;48:2561-67.
-
(1988)
Cancer Res
, vol.48
, pp. 2561-2567
-
-
Sondel, P.M.1
Kohler, P.C.2
Hank, J.A.3
Moore, K.H.4
Rosenthal, N.S.5
Sosman, J.A.6
-
7
-
-
0028106484
-
Randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma: An interim report
-
Yang JC, Topalian SL, Parkinson D, Schwartzentruber DJ, Weber JS, Ettinghausen SE, et al. Randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma: an interim report. J Clin Oncol 1994;12:1572-76.
-
(1994)
J Clin Oncol
, vol.12
, pp. 1572-1576
-
-
Yang, J.C.1
Topalian, S.L.2
Parkinson, D.3
Schwartzentruber, D.J.4
Weber, J.S.5
Ettinghausen, S.E.6
-
8
-
-
0024544021
-
A Phase II study of interleukin-2 and lymphokine-activated killer cells in patients with metastatic malignant melanoma
-
Dutcher JP, Creekmore S, Weiss GR, Margolin K, Markowitz AB, Roper M, et al. A Phase II study of interleukin-2 and lymphokine-activated killer cells in patients with metastatic malignant melanoma. J Clin Oncol 1989;7:477-85.
-
(1989)
J Clin Oncol
, vol.7
, pp. 477-485
-
-
Dutcher, J.P.1
Creekmore, S.2
Weiss, G.R.3
Margolin, K.4
Markowitz, A.B.5
Roper, M.6
-
9
-
-
0028266553
-
Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin-2
-
Rosenberg SA, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, Parkinson DR, et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin-2. JAMA 1994;271:907-13.
-
(1994)
JAMA
, vol.271
, pp. 907-913
-
-
Rosenberg, S.A.1
Yang, J.C.2
Topalian, S.L.3
Schwartzentruber, D.J.4
Weber, J.S.5
Parkinson, D.R.6
-
10
-
-
0027529476
-
Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer
-
Rosenberg SA, Lotze MT, Yang JC, Topalian SL, Chang AE, Schwartzentruber DJ, et al. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst 1993;85:622-32.
-
(1993)
J Natl Cancer Inst
, vol.85
, pp. 622-632
-
-
Rosenberg, S.A.1
Lotze, M.T.2
Yang, J.C.3
Topalian, S.L.4
Chang, A.E.5
Schwartzentruber, D.J.6
-
11
-
-
0027524697
-
Randomized Phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma
-
Sparano JA, Fisher RI, Sunderland M, Margolin K, Ernest ML, Sznol M, et al. Randomized Phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma. J Clin Oncol 1993;11:1969-77.
-
(1993)
J Clin Oncol
, vol.11
, pp. 1969-1977
-
-
Sparano, J.A.1
Fisher, R.I.2
Sunderland, M.3
Margolin, K.4
Ernest, M.L.5
Sznol, M.6
-
12
-
-
0025085675
-
Interleukin-2 therapy in patients with metastatic malignant melanoma: A phase II study
-
Parkinson DR, Abrams JS, Wiernik PH, Rayner AA, Margolin KA, Van Echo DA, et al. Interleukin-2 therapy in patients with metastatic malignant melanoma: a phase II study. J Clin Oncol 1990;8:1650-56.
-
(1990)
J Clin Oncol
, vol.8
, pp. 1650-1656
-
-
Parkinson, D.R.1
Abrams, J.S.2
Wiernik, P.H.3
Rayner, A.A.4
Margolin, K.A.5
Van Echo, D.A.6
-
13
-
-
0023868863
-
Effectiveness and tolerability of low-dose cyclophosphamide and low-dose intravenous interleukin-2 in disseminated melanoma
-
Mitchell MS, Kempf RA, Harel W, Shau H, Boswell WD, Lind S, et al. Effectiveness and tolerability of low-dose cyclophosphamide and low-dose intravenous interleukin-2 in disseminated melanoma. J Clin Oncol 1988;6:409-24.
-
(1988)
J Clin Oncol
, vol.6
, pp. 409-424
-
-
Mitchell, M.S.1
Kempf, R.A.2
Harel, W.3
Shau, H.4
Boswell, W.D.5
Lind, S.6
-
14
-
-
0002027157
-
The modified group C experience - Phase III randomized trials of IL-2 vs IL-2/ LAK in advanced renal cell carcinoma and advanced melanoma
-
abstr 714
-
McCabe MS, Stablein D, Hawkins MJ: The modified group C experience - phase III randomized trials of IL-2 vs IL-2/ LAK in advanced renal cell carcinoma and advanced melanoma. Proc Am Soc Clin Oncol 1991;10:213; (abstr 714).
-
(1991)
Proc Am Soc Clin Oncol
, vol.10
, pp. 213
-
-
McCabe, M.S.1
Stablein, D.2
Hawkins, M.J.3
-
15
-
-
0025947455
-
Phase II study of intravenous bolus recombinant interleukin-2 in advanced malignant melanoma: Southwest oncology group study
-
Whitehead RP, Kopecky KJ, Samson MK, Costanzi JJ, Natale RB, Feun LG, et al. Phase II study of intravenous bolus recombinant interleukin-2 in advanced malignant melanoma: southwest oncology group study. J Natl Cancer Inst 1991;83:1250-52.
-
(1991)
J Natl Cancer Inst
, vol.83
, pp. 1250-1252
-
-
Whitehead, R.P.1
Kopecky, K.J.2
Samson, M.K.3
Costanzi, J.J.4
Natale, R.B.5
Feun, L.G.6
-
16
-
-
0025361846
-
Metastatic malignant melanoma treated with combined bolus and continuous infusion interleukin-2 and lymphokine-activated killer cells
-
Bar MH, Sznol M, Atkins MB, Ciobanu N, Micetich KC, Boldt DH, et al. Metastatic malignant melanoma treated with combined bolus and continuous infusion interleukin-2 and lymphokine-activated killer cells. J Clin Oncol 1990;8:1138-47.
-
(1990)
J Clin Oncol
, vol.8
, pp. 1138-1147
-
-
Bar, M.H.1
Sznol, M.2
Atkins, M.B.3
Ciobanu, N.4
Micetich, K.C.5
Boldt, D.H.6
-
17
-
-
4243418443
-
Treatment of metastatic melanoma with continuous intravenous (CIV) IL2 ± LAK cells: A randomized trial
-
Abstract 1080
-
Richards JM, Bajorin DF, Vogelzang NJ, Houghton AN, Seigler HF, Sell K, et al. Treatment of metastatic melanoma with continuous intravenous (CIV) IL2 ± LAK cells: a randomized trial. Proc Am Soc Clin Oncol 1990;9:279. (Abstract 1080).
-
(1990)
Proc Am Soc Clin Oncol
, vol.9
, pp. 279
-
-
Richards, J.M.1
Bajorin, D.F.2
Vogelzang, N.J.3
Houghton, A.N.4
Seigler, H.F.5
Sell, K.6
-
18
-
-
0025974181
-
A Phase II study of high-dose continuous infusion interleukin-2 with lymphokine-activated killer cells in patients with metastatic melanoma
-
Dutcher JP, Gaynor ER, Boldt DH, Doroshow JH, Bar MH, Sznol M, et al. A Phase II study of high-dose continuous infusion interleukin-2 with lymphokine-activated killer cells in patients with metastatic melanoma. J Clin Oncol 1991;9:641-48.
-
(1991)
J Clin Oncol
, vol.9
, pp. 641-648
-
-
Dutcher, J.P.1
Gaynor, E.R.2
Boldt, D.H.3
Doroshow, J.H.4
Bar, M.H.5
Sznol, M.6
-
19
-
-
0027021026
-
Traitement du mélanome malin métastatique par l'interleukine-2
-
Dorval T, Fridman WH, Mathiot C, Sastre X, Pouillart P, et al. Traitement du mélanome malin métastatique par l'interleukine-2. Bull Cancer 1992;79:781-87.
-
(1992)
Bull Cancer
, vol.79
, pp. 781-787
-
-
Dorval, T.1
Fridman, W.H.2
Mathiot, C.3
Sastre, X.4
Pouillart, P.5
-
20
-
-
0027479510
-
Inpatient continuous-infusion interleukin-2 in 788 patients with cancer
-
Dillman RO, Church C, Oldham RK, West WH, Schwartzberg L, Birch R, et al. Inpatient continuous-infusion interleukin-2 in 788 patients with cancer. Cancer 1993;71:2358-70.
-
(1993)
Cancer
, vol.71
, pp. 2358-2370
-
-
Dillman, R.O.1
Church, C.2
Oldham, R.K.3
West, W.H.4
Schwartzberg, L.5
Birch, R.6
-
21
-
-
0024849183
-
Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer
-
Rosenberg SA, Lotze MT, Yang JC, Linehan M, Seipp C, Calabro S, et al. Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer. J Clin Oncol 1989;7:1863-74.
-
(1989)
J Clin Oncol
, vol.7
, pp. 1863-1874
-
-
Rosenberg, S.A.1
Lotze, M.T.2
Yang, J.C.3
Linehan, M.4
Seipp, C.5
Calabro, S.6
-
22
-
-
0027315222
-
Interferon-α and interleukin-2 in the treatment of metastatic melanoma
-
Keilholz U, Scheibenbogen C, Tilgen W, Bergmann L, Weidmann E, Seither E, et al. Interferon-α and interleukin-2 in the treatment of metastatic melanoma. Cancer 1993; 72:607-14.
-
(1993)
Cancer
, vol.72
, pp. 607-614
-
-
Keilholz, U.1
Scheibenbogen, C.2
Tilgen, W.3
Bergmann, L.4
Weidmann, E.5
Seither, E.6
-
23
-
-
0026734180
-
Sequential chemoimmunotherapy in the treatment of metastatic melanoma
-
Richards JM, Mehta N, Ramming K, Skosey P. Sequential chemoimmunotherapy in the treatment of metastatic melanoma. J Clin Oncol 1992;10:1338-43.
-
(1992)
J Clin Oncol
, vol.10
, pp. 1338-1343
-
-
Richards, J.M.1
Mehta, N.2
Ramming, K.3
Skosey, P.4
-
24
-
-
0027486041
-
Sequential chemoimmunotherapy with cisplatin, interleukin-2, and interferon alfa-2a for metastatic melanoma
-
Khayat D, Borel C, Tourani JM, Benhammouda A, Antoine E, Rixe O, et al. Sequential chemoimmunotherapy with cisplatin, interleukin-2, and interferon alfa-2a for metastatic melanoma. J Clin Oncol 1993;11:2173-80.
-
(1993)
J Clin Oncol
, vol.11
, pp. 2173-2180
-
-
Khayat, D.1
Borel, C.2
Tourani, J.M.3
Benhammouda, A.4
Antoine, E.5
Rixe, O.6
-
25
-
-
0027723618
-
Role of recombinant interleukin-2 in combination with interferon-alfa and chemotherapy in the treatment of advanced melanoma
-
Legha SS, Buzaid AC. Role of recombinant interleukin-2 in combination with interferon-alfa and chemotherapy in the treatment of advanced melanoma. Semin Oncol 1993; 20:27-32.
-
(1993)
Semin Oncol
, vol.20
, pp. 27-32
-
-
Legha, S.S.1
Buzaid, A.C.2
|